Sabio Group has announced its new Wellbeing Companion solution is now available in the Genesys AppFoundry.
The Companion aims to boost contact centre wellbeing and performance through AI, analytics and human insight.
The AppFoundry listing makes it easier for organisations to access Sabio’s transformative approach to monitoring the wellbeing of agents in the contact centre.
This enables contact centres to reduce attrition, absence and presenteeism while empowering agents to deliver excellent customer experiences (CX).
“Wellbeing in the contact centre is about creating an environment that supports advisors’ wellbeing and empowers their performance,” said Dr. Phoebe Asquith, a Senior Business Consultant at Sabio. “With our Wellbeing Companion now being made available on the Genesys’ AppFoundry, it’s even simpler for companies to build a culture of care and high performance.”
The Wellbeing Companion is part of a wider Wellbeing Programme from Sabio which includes psychology-based discovery, Consultancy Services and ongoing strategic Success Management.
The trio forms a holistic, tailored and data-led wellbeing programme that places employee welfare at the forefront of organisational culture.
The Companion’s AppFoundry listing follows on from the solution being shortlisted in Tomorrow’s Health & Safety Awards Guide 2024, which recognises the most innovative health and safety products set to make a real difference for UK workplaces.
The post Sabio’s Wellbeing Companion Now Available on the Genesys AppFoundry appeared first on HIPTHER Alerts.

 
Bybit, one of the world’s top three crypto exchanges by trading volume, today celebrates a monumental milestone: surpassing 30 million registered users globally. This remarkable achievement comes alongside a period of exceptional growth, solidifying Bybit as a frontrunner in the blockchain industry.
Market Share Soars, User Trust Flourishes
Bybit’s market share in spot trading has skyrocketed from 2% in 2023 to a staggering 9.3% in 2024, a nearly 400% surge according to the latest Kaiko Research quarterly report. This significant leap from the previous year’s 7.3% firmly establishes Bybit as a leader in cryptocurrency exchange.
Bybit attributes this growth to its unwavering commitment to user security and trust. The company prioritizes asset safety through the regular publication of proof-of-reserve audits, ensuring transparency and accountability with user funds. Additionally, Bybit boasts an impeccable security record, with no major breakdowns or hacking incidents since its inception in 2018.
This dedication to security and transparency is further validated by industry recognition. Bybit has received a perfect 10/10 Trust Score from CoinGecko and an ‘AA’ rating in the recent CCData Crypto Exchange Benchmark Report.
“Reaching 30 million registered users is a humbling achievement, and it wouldn’t be possible without the unwavering support of our vibrant global crypto community,” said Ben Zhou, Co-founder and CEO of Bybit. “We are incredibly grateful for their trust and remain committed to providing best-in-class, reliable services tailored to local needs. Bybit actively collaborates with regulators worldwide to ensure compliance and responsible innovation.”
Looking Forward: Bridging the Gap to Web3
Bybit has consistently been at the forefront of Web3 innovation, reshaping how users interact with the blockchain ecosystem through user-centric and engaging platforms. In 2024, we have expanded our suite of offerings with breakthrough solutions like the Airdrop Arcade, NFT Pro, and Inscription Marketplaces.
These platforms are meticulously designed not only to lower entry barriers and simplify the user experience but also to enrich it by curating opportunities to invest in and support a diverse range of promising, trending, and blue-chip tokens and projects. Our most recent Solana Fiesta and Bitcoin economy livestream introduced many Web3-curious individuals to the fast-growing ecosystems and their opportunities.
This curation consistently ensures that our users have access to the most rewarding and reliable opportunities in the Web3 space, making participation not only easier but also more enjoyable through gamification and advanced data intelligence. This commitment extends to the upcoming launch of Bybit Web3 DEX Pro, a cutting-edge decentralized exchange platform powered by revolutionary i-SMART data intelligence technology. This represents Bybit’s commitment to innovation that empowers, providing tools that not only meet but exceed the needs of modern traders and investors.
“Today’s milestone signifies more than just numbers; it’s a testament to our ongoing dedication to revolutionizing the crypto landscape,” emphasized Zhou. “Bybit remains committed to shaping the future of crypto. We will continue to uphold the values of listening, caring, and improving, to serve our 30 million users with the most professional products. Protecting the interests of our clients will be ingrained in all product designs. We envision a world where Web3 empowers every individual, where financial inclusivity is not just a goal but a reality.”
The post Bybit Reaches 30 Million Registered Users, Marking Explosive Growth and Industry Leadership into Web3 appeared first on HIPTHER Alerts.

 
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the “Global Next Generation Drug Conjugates Market – By Type (Peptide Receptor Radionuclide Therapy, Ligand mediated RNAi Conjugate, Ligand Conjugated Anti Sense Medicine and Peptide Drug Conjugate), By Type of Targeting Ligand (Amino Sugar, Peptide, Lipid, Small Molecule and Virus-like Particles), By Type of Payload (Peptide, Small Molecule, Oligonucleotide, Radionuclide), By Type of Therapy (Monotherapy, Combination Therapy), By Route of Administration, By Target Indications, By Region, Trends, Industry Competition Analysis, Revenue and Forecast To 2031.”
According to the latest research by InsightAce Analytic, the Global Next Generation Drug Conjugates Market is valued at US$ 2.61 Bn in 2023, and it is expected to reach US$ 7.94 Bn by 2031, with a CAGR of 15.1% during the forecast period of 2024-2031.
Request for Free Sample Pages: https://www.insightaceanalytic.com/report/next-generation-drug-conjugates-market/2482
Next Generation Drug Conjugates Market Report Scope:

Report Attribute

Specifications

Market Size Value In 2023

USD 2.61 Bn

Revenue Forecast In 2031

USD 7.94 Bn

Growth Rate CAGR

CAGR of 15.1% from 2024 to 2031

Quantitative Units

Representation of revenue in US$ Mn and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report Coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments Covered

By Type, By Targeting Ligand, By Payload, By Therapy, By Route of Administration, By Indications and By Region

Regional Scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country Scope

U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea

Growth of the next-generation drug conjugates market is driven by several factors, such as the recent accelerated approvals of various next-generation drug conjugates and the keen interest shown by the big pharma players in forging strategic alliances with the next-generation drug conjugate developers.
The ever-growing rise in medicare costs, along with the increasing burden of rare disease indications, prompted the stakeholders to look for alternatives to conventional therapies. As a result, the next-generation conjugates combine cytotoxic drugs with targeting agents, enhancing drug efficacy while reducing systemic toxicity. Deeper cellular penetration and permeability have emerged as viable targeted therapeutics for rare disease indications, including cancers.
List of Prominent Players in the Next Generation Drug Conjugates Market:

Advanced Accelerator Applications
Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Dicerna Pharmaceuticals
Geron Corporation
Ionis Pharmaceuticals
Dyne Therapeutics, Inc.
Ambrx Biopharma, Inc. (Johnson & Johnson Services, Inc.)
Vincerx Pharma
Tubulis Technologies
Nurix Therapeutics, Inc.
Other Prominent Players

Order 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2482
Market Dynamics:
Drivers:
The growth of the next generation drug conjugates (NGDCs) market is driven by several key factors. Technological advancements, such as improved linker technologies and versatile applications, enhance drug efficacy and safety.
The rising prevalence of chronic diseases, particularly cancer and genetic disorders, fuels demand for targeted therapies. Strategic industry collaborations and acquisitions, like Pfizer’s purchase of Seagen, accelerate innovation and market expansion. Favorable regulatory environments support expedited review processes and clear development guidelines. Additionally, significant investment in research and development, supported by funding and innovative platforms, drives the discovery and optimization of new NGDCs. These combined factors contribute to the rapid advancement and adoption of NGDCs in modern medicine.
Challenges:
The global next-generation drug conjugates market faces several formidable challenges. One of the primary obstacles is the high development cost associated with these therapies. The complex manufacturing processes required for drug conjugates involve sophisticated technology and stringent quality control measures, making scalability difficult and expensive. Additionally, the regulatory landscape presents significant hurdles; furthermore, gaining permission from regulatory bodies like the FDA and EMA is a time-consuming and expensive process that frequently necessitates substantial clinical trials to prove safety and efficacy.
Another major challenge is ensuring the stability and efficacy of drug conjugates. In order to be effective, these therapies must both release the therapeutic agent at the target site in a controlled manner and be stable under physiological conditions. Balancing these requirements while minimizing toxicity is a complex scientific and technical task. Patents and proprietary technology can restrict the capacity of new companies to enter the market and innovate, which further complicates intellectual property issues.
Regional Trends:
The North American next generation drug conjugates market is growing due to advanced healthcare infrastructure and significant R&D investments. Key players in the region are driving innovation in targeted cancer therapies, leveraging cutting-edge technologies for drug conjugation. The increasing cases of cancer and the rising demand for personalized medicine boost the market. Favorable regulatory policies further stimulate market growth, allowing swift approval and commercialization of novel drug conjugates.
Moreover, strategic collaborations between pharmaceutical companies and research institutions fuel the development of next-generation therapies. With a robust pipeline and expanding applications beyond oncology, the North American market for drug conjugates is poised for sustained expansion.
Curious About This Latest Version of The Report? Enquiry Before Buying:https://www.insightaceanalytic.com/enquiry-before-buying/2482
Recent Developments:

In April 2023, Novartis entered into a licensing agreement with 3B Pharmaceuticals. 3B Pharmaceuticals is a German-based company involved in the growth of peptide receptor radionuclide therapy (PRRT) candidates targeting fibroblast activation protein (FAP) receptors.
In March 2023, Japan-based PeptiDream signed strategic partnership with US-based RayzeBio to develop a peptide-radioisotope (RI) conjugate against Glypican-3 (“GPC3”) expressed in liver cancers.
In March 2023, The USFDA accepted Ionis Pharmaceutical’s New Drug Application (NDA) for its investigational antisense medication Eplontersen, which is intended for patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). After Amvuttra (vutrisiran) from Alnylam, Eplontersen will be the second medication licensed for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN).

For More Customization @ https://www.insightaceanalytic.com/customisation/2482
Segmentation of Next Generation Drug Conjugates Market-
Next Generation Drug Conjugates Market- By Type

Peptide Receptor Radionuclide Therapy (Peptide Radionuclide Conjugate)
Ligand-mediated RNAi Conjugate
Ligand Conjugated Antisense Medicine
Peptide Drug Conjugate

Next Generation Drug Conjugates Market- By Targeting Ligand

Amino Sugar
Lipid
Peptide
Small Molecule
Virus-like Particles

Next Generation Drug Conjugates Market- By Payload

Peptide
Small Molecule
Oligonucleotide
Radionuclide

Next Generation Drug Conjugates Market- By Therapy

Monotherapy
Combination Therapy

Next Generation Drug Conjugates Market- By Route of Administration

Intravenous
Subcutaneous
Others

Next Generation Drug Conjugates Market- By Indications

Gastroenteropancreatic Neuroendocrine Tumors
Prostate Cancer
Leptomeningeal Carcinomatosis caused by Breast Cancer Brain Metastases
Hereditary Transthyretin Amyloidosis
Atherosclerotic Cardiovascular Diseases
Severe Hypertriglyceridemia
Hereditary Angioedema
Acute Hepatic Porphyria
Primary Hyperoxaluria
Heterozygous Familial Hypercholesterolemia
Hemophilia
Low-Risk Myelodysplastic Syndrome
Myelofibrosis
Familial Chylomicronemia Syndrome
Alpha-1 Antitrypsin Deficiency Liver Disease

Next Generation Drug Conjugates Market- By Region
North America–

The US
Canada
Mexico

Europe–

Germany
The UK
France
Italy
Spain
Rest of Europe

Asia-Pacific–

China
Japan
India
South Korea
South East Asia
Rest of Asia Pacific

Latin America–

Brazil
Argentina
Rest of Latin America

 Middle East & Africa–

GCC Countries
South Africa
Rest of Middle East and Africa

Why should buy this report:

To receive a comprehensive analysis of the prospects for global next generation drug conjugates market
To receive industry overview and future trends of global next generation drug conjugates market
To analyze the next generation drug conjugates market drivers and challenges
To get information on the next generation drug conjugates market size value (US$ Mn) forecast till 2031
Major Investments, Mergers & Acquisition in global next generation drug conjugates market industry

Other Related Reports Published by InsightAce Analytic:
Antibody Drug Conjugates (ADCs) – Linker and Conjugation Technologies Market 
Conjugation and Labeling Services Market 
Peptide–Drug Conjugates (PDCs) Market
Antibody Discovery Market
The post Next Generation Drug Conjugates Market Worth USD 7.94 Billion to 2031 – Exclusive Report by InsightAce Analytic Pvt. Ltd. appeared first on HIPTHER Alerts.